Ambagon Therapeutics

The post Symeres collaborates with Ambagon Therapeutics on molecular glue research in colorectal cancer appeared first on Ambagon Therapeutics.

Symeres, Ambagon Therapeutics collaborate on molecular glue research in colorectal cancer

The Nature Index tracks the affiliations of scientific articles from high-quality publications. The research profile for Ambagon Therapeutics reflects the research output of authors from Ambagon Therapeutics who published articles in the 145 journals incl

The post Ambagon and academic collaborators awarded grant from the Michael J Fox Foundation to study 14-3-3:LRRK2 stabilizers as a neuroprotective therapy for Parkinson's Disease. appeared first on Ambagon Therapeutics.

The post 2022 Class of Emerging Companies appeared first on Ambagon Therapeutics.

The post Top Life Sciences Startups to Watch in 2023 appeared first on Ambagon Therapeutics.

SAN FRANCISCO, Calif., April 25, 2022 - Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered protein targets with novel molecular glues, today announced the appointment of Gideon Bollag, Ph.D., to its Scientific Advisory Board.

Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered protein targets with novel molecular glues, today announced the appointment of Gideon Bollag, Ph.D., to its Scientific

Modular platform enables development of molecular glue stabilizers addressing intrinsically disordered proteins, a largely undrugged target class Initial

Ambagon Therapeutics Launches With $85 Million Series A to Advance Pioneering Molecular Glue Platform and Progress Pipeline